AN2 Therapeutics, Inc.

In the quarter to June 2026, EPS grew 14.3% and free cash flow grew 7.91%, each against the same quarter a year earlier. Dividend growth for three consecutive years; insiders bought in the last twelve months.

3.38 0.22 −6.11%

Follow ANTX

Alert me

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
ROE Full definition →	+8 more TTM periods Free account	(45.91%)	(52.14%)	(44.56%)	(50.12%)
ROA Full definition →		(41.21%)	(45.67%)	(40.93%)	(46.06%)
ROIC Full definition →		0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →		(59.46%)	(68.68%)	(42.17%)	(48.75%)
Free Cash Flow per Share Full definition →		(0.99)	(0.99)	(0.92)	(0.69)
Free Cash Flow Full definition →		(29.87)	(29.83)	(31.28)	(30.68)
Other line items
Cash ROIC Full definition →		(24.42%)	(26.86%)	(18.73%)	(19.88%)
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Operating CF/Net income Full definition →		0.88	0.85	0.91	0.85
Depreciation/Fixed assets Full definition →		0.00	0.00	0.00	0.00
Capex/Depreciation Full definition →		0.00	0.00	0.00	0.00
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(0.99)	(0.99)	(0.92)	(0.69)
Capex per Share Full definition →		0.00	0.00	0.00	0.00

Columns are period end dates